Company intelligence / Profile preview

Hallura

Ownership: Private
Development stage: Commercial

Overview

Hallura’s hyaluronic acid dermal fillers use a novel crosslinking method based on Click Chemistry (“Bio-Orthogonal” cross-linking), resulting in low-modification HA gels that closely mimic natural HA. Clinical trials in Europe demonstrated excellent efficacy and safety with long-lasting results (>18 months), minimal swelling or side effects, high elasticity, easy molding for natural results, and significant stimulation of collagen I/III and elastin[1][2].

Therapeutic areas: Dermatology
Modalities: Hyaluronic acid-based dermal fillersBiologicDevice
Industry: Therapeutic Medical Devices

Drug pipeline

3 assets

Hallura HA filler (4 mg/ml)

Commercial

Indications: Facial fine lines

2 more assets in the full pipeline.

Request access →

Partnerships

Alon MedTech Ventures (investor/incubator)

Beyond the preview

Go deeper on Hallura.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hallura.

Explore the full profile